OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note published on Thursday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Down 33.6 %

NASDAQ:OPGN opened at $0.71 on Thursday. OpGen has a 1-year low of $0.66 and a 1-year high of $9.90. The company has a 50 day moving average price of $1.57 and a 200-day moving average price of $2.10.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.